CGON Stock Summary and Trading Ideas (CG Oncology | NASDAQ:CGON)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology trades on the NASDAQ stock market under the symbol CGON.

As of November 11, 2026, CGON stock price declined to $72.61 with 846,106 million shares trading.

CGON has a beta of 0.50, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.01 to the broad based SPY ETF.

CGON has a market cap of $6.49 billion. This is considered a Mid Cap stock.

Last quarter CG Oncology reported $2 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $960,416 and exceeded earnings estimates by $.18.

The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.

CGON has outperformed the market in the last year with a price return of +80.5% while the SPY ETF gained +12.6%. However, in the short term, CGON had mixed performance relative to the market. It has underperformed in the last 3 months, returning -5.2% vs -1.5% return in SPY. But in the last 2 weeks, CGON shares have fared better than the market returning +15.4% compared to SPY -1.3%.

CGON support price is $70.64 and resistance is $74.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.